According to a study conducted in the United Kingdom, statins can reduce the risk of dying from breast, prostate, lung, and bowel cancer.
Statins, according to a study conducted in the United Kingdom, can reduce the risk of dying from breast, prostate, lung, and bowel cancer. The results of the 14-year prospective trial were presented at the Frontiers in CardioVascular Biology meeting in Austria—the annual meeting of the European Society of Cardiology.
The data was a part of the Algorithm for Comorbidities, Associations, Length of stay and Mortality (ACALM) study, which followed nearly a million patients who were admitted to hospitals in the United Kingdom between January 1, 2000, and March 31, 2013. Of these, 7997 had lung cancer, 5481 had breast cancer, 4629 had prostate cancer, and 4570 had bowel cancer. The study had information on comorbidities such as high cholesterol, and the Office of National Statistics was the source of the morality data.
The trial itself was designed based on a previous discovery of an association between high cholesterol and the development of breast cancer, according to Paul Carter, MD, from the Aston Medical School in Birmingham. “Animal studies show that giving statins for high cholesterol can reduce the risk of breast cancer. We wanted to see if there was any effect of high cholesterol on mortality amongst cancer patients,” he said in an interview.
The study found that high cholesterol reduced the risk of death in patients with lung cancer by 22%, in patients with breast cancer by 43%, in patients with prostate cancer by 47%, and in patients with bowel cancer by 30%. The analysis adjusted for age, gender, ethnicity, and the 10 most common causes of death in the United Kingdom.
“Because we saw the association amongst all four cancers we studied, we think this effect is caused by medications used for high cholesterol such as statins. These findings are likely to be seen in other cancers as well but this is only speculation and would need to be confirmed by studies in different types of cancer,” Carter said.
According to Rahul Potluri, MD, the senior author on this study and founder of the ACLAM Study Unit, “The results of this study strengthen the argument for a clinical trial evaluating the possible protective effect of statins and other routinely used cardiovascular medications such as aspirin, blood pressure medications, beta-blockers and ACE inhibitors in patients with cancer. Whether it is statins and/or other cardiovascular drugs in combination that have an effect on mortality remains to be seen.”
Study Links COVID-19 Pandemic to Rise in Neoadjuvant Chemotherapy for Ovarian Cancer in US
April 17th 2024There was greater use of neoadjuvant chemotherapy among US patients with ovarian cancer (OC) during the COVID-19 pandemic to reduce potential COVID-19 exposure and cancer treatment-related complications.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
The Biden administration recently launched the Global Health Security Strategy, a new effort to combat the spread of infectious diseases; lawmakers zeroed in on the risks of massive consolidation in health care during the first congressional hearing on the Change Healthcare hack; the FDA recently announced the recall of a pair of heart devices linked to numerous deaths and injuries.
Read More